We are seeing great progress in pancreatic cancer research and the APGI and our collaborators are at the heart of this.


Journal articles published

  1. Hypermutation in Pancreatic Cancer. Humphris, JL, Patch A, Nones K, Bailey PJ, Johns AL, McKay S, Chang DK, Miller DK, Pajic M, Kassahn KS, Quinn MCJ, Bruxner TJC, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Stone A, Wilson PJ et al. Gastroenterology. 15 Nov 2016. [in press]
  2. Ampullary cancers harbor ELF3 tumor suppressor gene mutations and exhibit frequent WNT dysregulation. Gingras M, Covington KR, Chang DK, Donehower LA, Gill AJ, Ittmann MM, Creigton CJ, Johns AL, Shinbrot E, Dewal N, Fisher WE, Australian Pancreatic Cancer Genome Initiative, Pilarsky C et al. Cell Rep Feb 2016;14(4):907-19 doi:10.1016/j.celrep.2015.12.005
  3. Genomic analyses identify molecular subtypes of pancreatic cancer. Bailey P, Chang DK, Nones K, Johns A.L. et al; Nature Feb 2016 doi:10.1038/nature16965
  4. Precision medicine for advanced pancreas cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. Chantrill LA, Nagrial AM, Watson C, Johns AL, Martyn-Smith M, Simpson S, Mead S, Jones MD, Samra JS, Gill AJ, Watson N, Chin VT, Humphris JL, Chou A, Brown B, Morey A, Pajic M, Grimmond SM, Chang DK, Thomas D, Sebastian L, Sjoquist K, Yip S, Pavlakis N, Asghari R, Harvey S, Grimison P, Simes J, Biankin AV, Australian Pancreatic Cancer Genome Initiative (APGI) and the Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial Management Committee of the Australasian Gastrointestinal Trials Group (AGITG).  Clin Cancer Res. 2015 Apr 20. [Epub ahead of print].
  5. Whole genomes redefine the mutational landscape of pancreatic cancer. Waddell N, Pajic M, Patch A, Chang D, Kassahn K, Bailey P, Johns A, Miller D, et al Australian Pancreatic Cancer Genome Initiative, et al. Nature doi:10.1038/nature14169 Vol. 518 No 7540; 26 Feb 2015.
  6. SOX9 regulates ERB signaling in pancreatic cancer development. Grimont A, Pinho A, Cowley M, Augereau C, Mawson A, Giry-Laterriere M, Van den Steen G, Waddell N, Pajic M, Sempoux C, Wu J, Grimmond S, Biankin A, Lemaigre F, Rooman I, Jacquemin P; Gut published online October 21 2014.
  7. Clinical and pathologic features of familial pancreatic cancer. Humphris JL, Johns A, Simpson S, Cowley M, Pajic M, Chang D, Nagriall A,Chin V, Chantrill L, Pinese M, Mead RS,Gill A, Samra J, Kench J, Musgrove E, Tucker K, Spigelman A, Waddell N, Grimmond S, Biankin A, Australian Pancreatic Cancer Genome Initiative (APGI). Cancer 14 October 2014 doi:10.1002/cncr.28863.
  8. A workflow to increase verification rate of chromosomal structural rearrangements using high-throughput next generation sequencing. Quek K, Nones K, Patch AM, Fink JL, Newell F, Cloonan N, Miller D, Fadlullah MZ, Kassahn K, Christ AN, Bruxner TJ, Manning S, Harliwong I, Idrisoglu S, Nourse C, Nourbakhsh E, Wani S, Steptoe A, Anderson M, Holmes O, Leonard C, Taylor D, Wood S, Xu Q, Australian Pancreatic Cancer Genome Initiative, Wilson P, Biankin AV, Pearson JV, Waddell N, Grimmond SM. Biotechniques 2014 Jul 1;57(1):31-8. doi: 10.2144/000114189.
  9. Understanding how consumers would like to engage in the research decision-making process. Holliday C, Kwok J, Yip K, Axford C, Simpson S, Johns A, Zeps N. Cancer Forum July 2014; Vol 38:2.
  10. Returning individual research results for genome sequences of pancreatic cancer. Johns AL, Miller DK, Simpson S, Gill A, Kasshan K, Samra J, Tucker K, Andrews L, Chang D, Waddell N, Pajic M, Australian Pancreatic Cancer Genome Initiative (APGI), Pearson J, Grimmond S, Biankin A, Zeps N. Genome Medicine 29 May 2014, 6:42 doi:10.1186/gm558
  11. Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. Nones K, Waddell N, Song S, Patch AM, Miller D, Johns A, Wu J, Kassahn KS, Wood D, Bailey P, Fink L, Manning S, Christ AN, Nourse C, Kazakoff S, Taylor D, Leonard C, Chang DK, Jones MD, Thomas M, Watson C, Pinese M, Cowley M, Rooman I, Pajic M, Australian Pancreatic Cancer Genome Initiative (APGI), Butturini G, Malpaga A, Corbo V, Crippa S, Falconi M, Zamboni G, Castelli P, Lawlor RT, Gill AJ, Scarpa A, Pearson JV, Biankin AV, Grimmond SM. Intnl J Cancer. 2014 Sep 1;135(5):1110-8.
  12. Personalising pancreas cancer treatment: when tissue is the issue. Sjoquist KM, Chin V, Chantrill L, O’Connor C, Hemmings C, Chang D, Chou A, Pajic M, Johns AL, Nagrial A, Biankin A, Yip D. World J Gastroenterol. 2014 Jun 28;20(24):7849-7863. Review.
  13. Gemcitabine and CHK1 inhibition Potentiate EGFR-Directed Radioimmunotherapy against Pancreatic Ductal Adenocarcinoma. Al-Ejeh F, Pajic M, Shi W, Kalimutho M, Miranda M, Nagrial AM, Chou A, Biankin AV, Grimmond SM, Australian Pancreatic Cancer Genome Initiative (APGI), Brown MP, Khanna KK; Clin Cancer Res. 2014 May 16.
  14. Targeting mTOR dependency in pancreatic cancer. Morran DC, Wu J, Jamieson N, Mrowinska A, Kalna G, Karim S, Au A, Scarlett C, Chang D, Pajic M, Oien K, McKay C, Carter CR, Gillen G, Champion S, Pimlott S, Anderson K, Evans TRJ, Grimmond S, Biankin A, Sansom O, Australian Pancreatic Cancer Genome Initiative (APGI), Morton J. Gut April 2014; doi:10.1136/gutjnl-2013-306202.
  15. Adjuvant chemotherapy in elderly patients with pancreatic cancer. Nagrial AM, Chang DK, Nguyen NQ, Johns AL, Chantrill LA, Humphris JL, Chin VT, Samra JS, Gill AJ, Pajic M, Australian Pancreatic Cancer Genome Initiative, Pinese M, Colvin EK, Scarlett CJ, Chou A, Kench JG, Sutherland RL, Horvath LG, Biankin AV. Br J Cancer 2013 Nov 21 Doi: 10.1038/bjc2013.722.
  16. Signatures of mutational processes in human cancer. Alexandrov LB, Nik=Zainal S, Wedge DC, Aparicio SA, Behjati S, Biakin AV et al. Nature 2013 Aug 22;500(7463) 415-21.
  17. Early epigenetic downregulation of WNK2 kinase during pancreatic ductal adenocarcinoma development. Dutruel C, Bergmann F, Rooman I, Zucknick M,Weichenhan D, Geiselhart L, Kaffenberger T, Rachakonda PS, Bauer A, Giese N, Hong C, Xie H, Costello JF, Hoheisel J, Kumar R, Rehli M, Schirmacher P, Werner J, Plass C, Popanda O, Schmezer P. Oncogene 2013 Aug 5. Doi:10.1038/onc.2013.312
  18. Somatic Point Mutation Calling in Lo.w Cellularity Tumors. Kassahn K, Holmes O, Nones K, Patch A, Miller D, Christ A, Harliwong I, Bruxner T, Xu Q, Anderson M, Wood S, Leonard C, Taylor D, Newell F, Song S, Idrisoglu S, Nourse C, Nourbakhsh E, Manning S, Wani S, Steptoe A, Pajic M, Cowley M, Pinese M, Chang D, Gill A, Johns A, Wu J, Wilson P, Fink L, Biankin A, Waddell N, Grimmond S, Pearson J; Plos One 2013 Nov. Vol.8 Issue 11 e74380.
  19. Clinical and molecular characterization of HER2 amplified pancreatic cancer. Chou A, Waddell N, Cowley M, Gill A, Chang D, Patch A, Nones K, Wu J, Pinese M, Johns A, Miller D, Kassahn K, Nagrial A, Wasam H, Goldstein D, Toon C, Chin V, Chantrill L, Humphris J, Mead R, Rooman I, Samra J, Pajic M, Musgrove E, Pearson J, Morey A, Grimmond S, Biankin A. (2013 Aug) Genome Medicine 5:78 doi:10.1186/gm482.
  20. Neuropilin-2 promotes extravasation and metastasis by interacting with endothelial a5 integrin. Cao Y, Hoeppner L, Bach S, Guo Y, Wang E, Wu J, Cowley MJ, Chang DK, Waddell N, Grimmond SM, Biankin AV, Daly RJ, Zheng X, Mukhopadhyay D. (2013) Cancer Res. May 20
  21. Understanding pancreatic cancer genomes. Cowley MJ, Chang DK, Pajic M, Johns AL, Waddell N, Grimmond SM, Biankin AV.  J Hepatobiliary Pancreat Sci. 2013 May 10.
  22. Histomolelcular phenotypes and outcome in adenocarcinoma of the ampulla of vater. Chang DK, Jamieson NB, Johns AL, Scarlett CJ, Pajic M, Chou A, Pinese M, Humphris JL, Jones MD, Toon C, Nagrial AM, Chantrill LA, Chin VT, Pinho AV, Rooman I, Cowley MJ, Wu J, Mead RS, Colvin EK, Samra JS, Corbo V, Bassi C, Falconi M, Lawlor RT, Crippa S, Sperandio N, Bersani S, Dickson EJ, Mohamed MA, Oien KA, Foulis AK, Musgrove EA, Sutherland RL, Kench JG, Carter CR, Gill AJ, Scarpa A, McKay CJ, Biankin AV. (2013) J Clin Oncol. April 1:31(10):1348-56
  23. Sirtuin-1 regulates acinar-to-ductal metaplasia and supports cancer cell viability in pancreatic cancer. Wauters E, Sanchez-Arevalo, Lobo VJ, Pinho AV, Mawson A, Herranz D, Wu J, Cowley MJ, Colvin EK, Njicop EN, Sutherland RL, Liu T, Serrano M, Bouwens L, Real FX, Biankin AV, Rooman I. Cancer Res 2013 April 1; 73(7):2357-67
  24. Contribution of bone marrow derived cells to the pancreatic tumour microenvironment. Scarlett CJ. Front Physiol. 2013;4:56 dpi: 10.3389/fphys.2013.00056. Epub 2013 Mar 26.
  25. The histone deacetylase SIRT2 stabilizes Myc oncoproteins. Liu PY, Xu N, Malyukova A, Scarlett CJ, Sun YT, Zhang XD, Ling D, Su SP, Nelson C, Chang DK, Koach J, Tee AE, Haaber M, Norris MD, Toon C, Rooman I, Xue C, Cheung BB, Kumar S, Marshall GM, Biankin AV, Liu T. Cell Death Differ. 2013 Mar;20(3):503-14
  26. Novel cancer drivers: mining the kinome. Biankin AV, Grimmond SM. Genome Med. 2013 Feb 28:5(2):19
  27. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Biankin AV, Waddell N, Kassahn K, Gingras M-C, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch A-M, Wu J, Chang DK, Cowley MJ, Gardiner BB, Song S, Harliwong I, Idrisoglu S, Nourse C, Nourbakhsh E, Manning S, Wani S, Gongora M, Pajic M, Scarlett CJ, Gill AJ, Pinho AV, et al. Nature. 2012 Nov; doi:10.1038/nature11547 [PMID:23103869]
  28. Factors influencing intention to undergo whole genome screening in future healthcare: a single-blind parallel-group randomised trial. Fisher A, Bonner C, Biankin AV, Juraskova I. Prev Med. 2012 Nov; 55(5):514-20
  29. qpure: A tool to estimate tumor cellularity from genome-wide single nucleotide polymorphism profiles. Song S, Nones K, Miller D, Harliwong I, Kassahn KkS, Pinese M, Pajic M, Gill AJ, Johns AL, Anderson M, Holmes O, Leonard C, Taylor D, Wood S, Xu Q, Newell F, Cowley MJ, Wu J, Wilson P, Fink L, Biankin AV,Waddell N, Grimmonds SM, Pearson JV. PLoS One. 2012; 7(9):e45835. Epub 2012 Sep 25.
  30. RON is not a prognostic marker for resectable pancreatic cancer. Tactacan CM, Chang, DK, Cowley MJ, Humphrey ES, Wu J, Gill AJ, Chou A, Nones K, Grimmond SM, Sutherland RL, Biankin AV, Daly RJ and Australian Pancreatic Genome Initiative. BMC Cancer. 2012 Sep; doi:10.1186/1471-2407-12-395 [PMID:22958871]
  31. Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors. Rottenberg S, Vollebergh MA, de Hoon B, de Ronde J, Schouten PC, Kersbergen A, Zander SA, Pajic M, Jaspers JE, Jonkers M, Lodén M, Sol W, van der Burg E, Wesseling J, Gillet JP, Gottesman MM, Gribnau J, Wessels L, Linn SC, Jonkers J, Borst P. Cancer Res. 2012 May; doi:10.1158/0008-5472.CAN-11-4201 [PMID:22396490]
  32. The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Pérez-Mancera PA, Rust AG, van der Weyden L, Kristiansen G, Li A, Sarver AL, Silverstein KAT, Grützmann R, Aust D, Rümmele P, Knösel T, Herd C, Stemple DL, Kettleborough R, Brosnan JA, Li A, Morgan R, Knight S, Yu J, Stegeman S, Collier LS, ten Hoeve JJ, de Ridder J, Klein AP, Goggins M, Hruban RH, Chang DK, Biankin AV, Grimmond SM, APGI, Wessels LFA, Wood SA, Iacobuzio-Donahue CA, Pilarsky CA, Largaespada DA, Adams DJ, Tuveson DA. Nature. 2012 Apr; doi:10.1038/nature11114
  33. Sleeping Beauty Mutagenesis Reveals Cooperating Mutations and Pathways in Pancreatic Adenocarcinoma. Mann KM, Ward JM, Yew CCK, Kovochich A, Dawson DW, Black MA, Brett BT, Sheets TE, Dupuy AJ, Chang DK, Biankin AV, Waddell N, Khassan KS, Grimmond SM, APGI, Rust AG, Adams DJ, Jenkins NA, Copeland NG. Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):5934-41. Epub 2012 Mar 15. [PMID: 22421440]
  34. Pancreatic ductal adenocarcinoma and acinar cells: a matter of differentiation and development? Rooman I, Real FX. Gut 2012 Mar; 61(3):449-48
  35. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Humphris JL, Chang DK, Johns AL, Scarlett CJ, Pajic M, Jones MD, Colvin EK, Nagrial A, Chin VT, Chantrill LA, Samra JS, Gill AJ, Kench JG, Merrett ND, Das A, Musgrove EA, Sutherland RL and Biankin AV.  Ann Oncol. 2012 Jan 11. [PMID: 22241899]
  36. PINA v2.0 Mining Interactome modules. Cowley MJ, Pinese M, Kassahn KS, Waddell N, Pearson JV, Grimmond SM, Biankin AV, Hautaniemi S, Wu J. PINA v2.0: Nucleic Acids Res. 2012 Jan; 40(Database issue):D862-5. [PMID: 22067443]
  37. Long term nutritional status and quality of life following major upper gastrointestinal surgery – a cross-sectional study. Carey S, Storey D, Biankin AV, Martin D, Young J, Allman-Farinelli M. Clin Nutr. 2011 Dec; 30(6):774-9.
  38. Recruitment and Activation of Pancreatic Stellate Cells from the Bone Marrow in Pancreatic Cancer: A Model of Tumor-Host Interaction. Scarlett CJ, Colvin EK, Pinese M, Chang DK, Morey AL, Musgrove EA, Pajic M, Apte M, Henshall SM, Sutherland RL, Kench JG, Biankin AV. LoS One. 2011;6(10):e26088. [PMID: 22022519]
  39. Molecular diagnostics in pancreatic cancer, Advances in Pancreatic Cancer Treatment. Chang DK, Grimmond SM, Biankin AV: Future Medicine Ltd, 2011, pp 20-35. doi: 10.2217/9781780840703
  40. Clinical and immunohistochemical features of 34 solid pseudopapillary tumours of the pancreas. Nguyen NQ, Johns AL, Gill AJ, Ring N, Chang DK, Clarkson A, Merrett ND, Kench JG, Colvin EK, Scarlett CJ and Biankin AV (2011). J Gastroenterol Hepatol. 2011 Feb;26(2):267-74. doi: 10.1111/j.1440-1746.2010.06466.x. [PMID: 21261715]
  41. Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes. Pajic M, Scarlett CJ, Chang DK, Sutherland RL and Biankin AV (2011). Hum Genet. 2011 Jul;130(1):93-101. Epub 2011 Apr 23. [PMID: 21516344]
  42. SIRT1 promotes N-Myc oncogenesis through a positive feedback loop involving the effects of MKP3 and ERK on N-Myc protein stability. Marshall GM, Liu PY, Gherardi S, Scarlett CJ, Bedalov A, Xu N, Iraci N, Valli E, Liind D, Thomas W, van Bekkum M, Sekyere E, Jankowski K Trahair T, Mackenzie KL, Haber M, Norris MD, Biankin AV, Perini G, Liu T. PLoS Genet. 2011 Jun;7(6):e1002135.
  43. Retinoid signalling in pancreatic cancer, injury and regeneration. Colvin EK, Susanto JM, Kench JG, Ong VN, Mawson A, Pinese M, Chang DK, Rooman I, O’Toole SA, Segara D, Musgrove EA, Sutherland RL, Apte MV, Scarlett CJ, Biankin AV.  PLoS One. 2011;6(12):e29075
  44. Precursor lesions in pancreatic cancer: morphological and molecular pathology. Scarlett CJ, Salisbury EL, Biankin AV and Kench JG (2011). Pathology. 2011 Apr;43(3):183-200. [PMID: 21436628]
  45. “How to Treat” Pancreatic Disease. Chang DK,Pavey DA, Biankin AV.  Australian Doctor. 10th June, 2011
  46. The road ahead: less travelled and more arduous than initially envisioned. Biankin AV, Chanock SJ. Hum Genet. 2011 130:1-2
  47. Somatic variation and cancer: therapies lost in the mix. Biankin AV, Hudson TJ, Hum Genet.  2011 July;130(1):79-91.
  48. P53-dependent regulation of growth, epithelial-esenchymal transition and stemness in normal pancreatic epithelial cells. Pinho AV, Rooman I and Real FX. Cell Cycle 2011 10:1312-1321
  49. Role of pancreatic stellate cells in pancreatic cancer metastasis. XuZ, Vonlaufen A, Phillips PA, Fiala-Beer E, Zhang X, Yang L, Biankin AV, Goldstein D, Pirola RM, Wilson JD, Apte M. Am. J. Pathol 2010 177:2585-2596.
  50. Management of pancreatic exocrine insufficiency: Australasian Pancreatic Club recommendations. Toouli J, Biankin AV, Oliver MR, Pearce CB, Wilson JS, Wray NH, Australian Pancreatic Club. Med J. Aust 2010. 193:461-7
  51. International network of cancer genome projects. The International Cancer Genome Consortium (2010). Nature. 2010 Apr 15;464(7291):993-8. [PMID: 20393554].
  52. Defining research priorities for pancreatic cancer in Australia: results sof a consensus development process. Robotin M, Jones S, Biankin AV Iverson D, Gooden H, Barraclough B, Penman A. Cancer Cause Control 2010 21:729-739.
  53. Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects. Marshall GM, Gherardi S, Xu N, Neiron Z, Trahair T, Scarlett CJ, Chang DK, Liu Pym, Janglowski K, Iraci N, Haber M, Norris MD, Keating J, Sekyere E, Jonquires G, Stossi F, Katzenellenbogen BS, Biankin AV, Perini G, Liu T. Oncogene. 2010 Nov 4;(44):5957-68.
  54. Hypoxia-inducible factor-1alpha regulates beta cell function in mouse and human islets. Cheng K, Ho K, Stokes R, Scott C, Lau SM, Hawthorne WJ, O’Connell PJ, Loudovaris T, Kay TW, Kulkarni RN, Okada T, Wang XL, Yim SH, Shah Y, Grey ST, Biankin AV, Kench JG, Laybutt DR, Gonzfalex FJ, Kahn CR, Gunton JE. J Clin Invest. 2010 June;120(6):2171-83
  55. Messina: a novel analyses tool to identify biologically relevant molecules in disease. Pinese M, Scarlett CJ, Kench JG, Colvin EK, Segara D, Henshall SM, Sutherland RL, Biankin AV. PLoS ONE, 2009;4(4): e5337.
  56. Real time introperative confocal laser microscopy-guided surgery. Nguyen NQ, Biankin AV, Leong RW, Chang DK, Cosman PH, Delaney P, Kench JG, Merrett ND. Ann Surg. 2009 May; 249(5):735-7.
  57. Taking optical biopsies with confocal endomicroscopy. Leong RW, Chang D, Merrett ND, Biankin AV. J Gastroenterol. Hepatol. 2009 Nov:24(11):1701-3.
  58. Synoptic reporting improves histopathological assessment of pancreatic resection specimens. Gill AJ, Johns AL, Eckstein RP, Samra J, Kaufman A, Chang DK, Merrett ND, Cosman PH, Smith RC, Biankin AV, Kench JG and NSWPCN. Pathology 2009 41:161-167.
  59. Role of endoscopic ultrasound in pancreatic cancer. Chang DK, Nguyen NQ, Merrett ND, Dixson H, Leong RW, Biankin AV. Expert Rev. Gastroenterol. Hepatol. 2009 Jun;3(3):293-303.
  60. Margin clearance and outcome in resected pancreatic cancer. Chang DK. Johns AL. Merrett ND. Gill AJ. Colvin EK. Scarlett CJ. Nguyen NQ. Leong RW. Cosman PH. Kelly MI. Sutherland RL. Henshall SM. Kench JG. Biankin AV. J Clin Oncol. 2009 Jun 10;27(17):2855-62. Epub 2009 Apr 27. [PMID: 19398572].
  61. Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer. Biankin AV. Kench JG. Colvin EK. Segara D. Scarlett CJ. Nguyen NQ. Chang DK. Morey AL. Lee CS. Pinese M. Kuo SC. Susanto JM. Cosman PH. Lindeman GJ. Visvader JE. Nguyen TV. Merrett ND. Musgrove EA. Henshall SM. Sutherland RL. Gastroenterology. 2009 Aug;137(2):558-68, 568.e1-11. [PMID: 19376121].